Molecular Roots of Down Syndrome Unraveled, Sanford-Burnham Medical Research Institute Study
Published: Mar 25, 2013
“In the brain, SNX27 keeps certain receptors on the cell surface—receptors that are necessary for neurons to fire properly,” said Huaxi Xu, Ph.D., professor in Sanford-Burnham’s Del E. Webb Neuroscience, Aging and Stem Cell Research Center and senior author of the study. “So, in Down syndrome, we believe lack of SNX27 is at least partly to blame for developmental and cognitive defects.”
SNX27’s role in brain function
Xu and colleagues started out working with mice that lack one copy of the snx27 gene. They noticed that the mice were mostly normal, but showed some significant defects in learning and memory. So the team dug deeper to determine why SNX27 would have that effect. They found that SNX27 helps keep glutamate receptors on the cell surface in neurons. Neurons need glutamate receptors in order to function correctly. With less SNX27, these mice had fewer active glutamate receptors and thus impaired learning and memory.
SNX27 levels are low in Down syndrome
Then the team got thinking about Down syndrome. The SNX27-deficient mice shared some characteristics with Down syndrome, so they took a look at human brains with the condition. This confirmed the clinical significance of their laboratory findings—humans with Down syndrome have significantly lower levels of SNX27.
Next, Xu and colleagues wondered how Down syndrome and low SNX27 are connected—could the extra chromosome 21 encode something that affects SNX27 levels? They suspected microRNAs, small pieces of genetic material that don’t code for protein, but instead influence the production of other genes. It turns out that chromosome 21 encodes one particular microRNA called miR-155. In human Down syndrome brains, the increase in miR-155 levels correlates almost perfectly with the decrease in SNX27.
Xu and his team concluded that, due to the extra chromosome 21 copy, the brains of people with Down syndrome produce extra miR-155, which by indirect means decreases SNX27 levels, in turn decreasing surface glutamate receptors. Through this mechanism, learning, memory, and behavior are impaired.
Restoring SNX27 function rescues Down syndrome mice
If people with Down syndrome simply have too much miR-155 or not enough SNX27, could that be fixed? The team explored this possibility. They used a noninfectious virus as a delivery vehicle to introduce new human SNX27 in the brains of Down syndrome mice.
“Everything goes back to normal after SNX27 treatment. It’s amazing—first we see the glutamate receptors come back, then memory deficit is repaired in our Down syndrome mice,” said Xin Wang, a graduate student in Xu’s lab and first author of the study. “Gene therapy of this sort hasn’t really panned out in humans, however. So we’re now screening small molecules to look for some that might increase SNX27 production or function in the brain.”
This research was funded by the U.S. National Institutes of Health (National Institute on Aging grants R01AG038710, R01AG021173, R01AG030197, R01AG044420; National Institute of Neurological Disorders and Stroke grants R01NS046673, P30NS076411; Eunice Kennedy Shriver National Institute of Child Health & Human Development grant P01HD29587; National Institute of Environmental Health Sciences grant P01ES016738), Alzheimer's Association, American Health Assistance Foundation, National Natural Science Foundation of China, 973 Prophase Project, Natural Science Funds for Distinguished Young Scholar of Fujian Province, Program for New Century Excellent Talents in Universities, Fundamental Research Funds for the Central Universities, and Fok Ying Tung Education Foundation.
The study was co-authored by Xin Wang, Sanford-Burnham; Yingjun Zhao, Sanford-Burnham and Xiamen University; Xiaofei Zhang, Sanford-Burnham; Hedieh Badie, Sanford-Burnham; Ying Zhou, Sanford-Burnham; Yangling Mu, Salk Institute; Li Shen Loo, Institute of Molecular and Cell Biology, Singapore; Lei Cai, Institute of Molecular and Cell Biology, Singapore; Robert C. Thompson, Sanford-Burnham; Bo Yang, Sanford-Burnham; Yaomin Chen, Sanford-Burnham; Peter F. Johnson, National Cancer Institute-Frederick; Chengbiao Wu, University of California, San Diego; Guojun Bu, Xiamen University; William C. Mobley, University of California, San Diego; Dongxian Zhang, Sanford-Burnham; Fred H. Gage, Salk Institute; Barbara Ranscht, Sanford-Burnham; Yun-wu Zhang, Sanford-Burnham and Xiamen University; Stuart A. Lipton, Sanford-Burnham and University of California, San Diego; Wanjin Hong, Institute of Molecular and Cell Biology, Singapore and Xiamen University; and Huaxi Xu, Sanford-Burnham and Xiamen University.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), California and Orlando (Lake Nona), Florida. For more information, visit us at sanfordburnham.org.